Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Ghaneh, Paula; H. Palmer, Daniel; Cicconi, Silvia; Jackson, Richard; Halloran, Christopher; Rawcliffe, Charlotte; Sripadam, Rajaram; Mukherjee, Somnath; Soonawalla, Zahir; Wadsley, Jonathan; Al-Mukhtar, Ahmed; J. Dickson, Euan; Graham, Janet; R. Jiao, Long; Wasan, Harpreet; S. Tait, Iain; Prachalias, Andreas; J. Ross, Paul; W. Valle, Juan; O’Reilly, Derek; Al‐Sarireh, Bilal; Gwynne, Sarah; Ahmed, Irfan; Connolly, Kate; Yim, Kein-Long; Cunningham, David; Armstrong, Thomas; Archer, Caroline; Roberts, Keith; Ting, Yuk; Springfeld, Christoph; Tjaden, Christine; Hackert, Thilo; W. Büchler, Markus; P. Neoptolemos, John

doi:10.1016/s2468-1253(22)00348-x

Public

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Published in The Lancet. Gastroenterology & hepatology • Dec 12, 2022

Authors:

Paula Ghaneh

Daniel H. Palmer

Silvia Cicconi

Abstract

Background Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the feasibility and efficacy of three different types of short-course neoadjuvant ther...

Subject

Medicine

Capecitabine

FOLFIRINOX

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!